CN114126612A - 遗传性血管性水肿的治疗 - Google Patents

遗传性血管性水肿的治疗 Download PDF

Info

Publication number
CN114126612A
CN114126612A CN202080043365.6A CN202080043365A CN114126612A CN 114126612 A CN114126612 A CN 114126612A CN 202080043365 A CN202080043365 A CN 202080043365A CN 114126612 A CN114126612 A CN 114126612A
Authority
CN
China
Prior art keywords
compound
formula
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080043365.6A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·保罗·费尼尔
萨利·路易斯·马什
安德烈亚斯·梅茨尔
迈克尔·戴维·史密斯
克里斯多夫·马丁·叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CN114126612A publication Critical patent/CN114126612A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN202080043365.6A 2019-06-14 2020-06-15 遗传性血管性水肿的治疗 Pending CN114126612A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
US62/861,725 2019-06-14
GB1910116.1 2019-07-15
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
CN114126612A true CN114126612A (zh) 2022-03-01

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080043365.6A Pending CN114126612A (zh) 2019-06-14 2020-06-15 遗传性血管性水肿的治疗

Country Status (34)

Country Link
US (1) US20220218680A1 (https=)
EP (2) EP4282474A3 (https=)
JP (3) JP7356518B2 (https=)
KR (1) KR102748728B1 (https=)
CN (1) CN114126612A (https=)
AR (1) AR119158A1 (https=)
AU (1) AU2020293614B2 (https=)
BR (1) BR112021024664A2 (https=)
CA (1) CA3142218A1 (https=)
CL (2) CL2021003244A1 (https=)
DK (1) DK3982960T3 (https=)
EA (1) EA202193019A1 (https=)
ES (1) ES2956471T3 (https=)
FI (1) FI3982960T3 (https=)
GB (1) GB201910116D0 (https=)
HR (1) HRP20230696T1 (https=)
HU (1) HUE063163T2 (https=)
IL (1) IL288615A (https=)
LT (1) LT3982960T (https=)
MA (1) MA56187B1 (https=)
MD (1) MD3982960T2 (https=)
MX (1) MX2021014557A (https=)
MY (1) MY205687A (https=)
PH (1) PH12021552966A1 (https=)
PL (1) PL3982960T3 (https=)
PT (1) PT3982960T (https=)
RS (1) RS64412B1 (https=)
SG (1) SG11202113304YA (https=)
SI (1) SI3982960T1 (https=)
SM (1) SMT202300261T1 (https=)
TW (1) TW202112370A (https=)
UA (1) UA129869C2 (https=)
WO (1) WO2020249977A1 (https=)
ZA (1) ZA202110685B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003386A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20230381162A1 (en) * 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2026003532A1 (en) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sebetralstat for the treatment of anxiety associated with hereditary angioedema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
US20130210809A1 (en) 2010-07-14 2013-08-15 Christelle Boléa Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
MY174018A (en) 2013-05-23 2020-03-04 Kalvista Pharmaceuticals Ltd Heterocyclic derivates
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003386A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Also Published As

Publication number Publication date
CL2023000639A1 (es) 2023-10-30
AU2020293614B2 (en) 2024-08-15
NZ782935A (en) 2025-02-28
SG11202113304YA (en) 2021-12-30
KR102748728B1 (ko) 2024-12-30
CA3142218A1 (en) 2020-12-17
DK3982960T3 (da) 2023-08-21
AU2020293614A1 (en) 2022-01-27
MD3982960T2 (ro) 2023-12-31
WO2020249977A1 (en) 2020-12-17
JP2023166406A (ja) 2023-11-21
SI3982960T1 (sl) 2023-10-30
LT3982960T (lt) 2023-08-25
PT3982960T (pt) 2023-09-26
JP7356518B2 (ja) 2023-10-04
ES2956471T3 (es) 2023-12-21
BR112021024664A2 (pt) 2022-05-31
US20220218680A1 (en) 2022-07-14
RS64412B1 (sr) 2023-09-29
JP7688078B2 (ja) 2025-06-03
CL2021003244A1 (es) 2022-09-30
EP4282474A3 (en) 2024-02-14
EP3982960A1 (en) 2022-04-20
HRP20230696T1 (hr) 2023-10-13
PL3982960T3 (pl) 2024-01-15
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
SMT202300261T1 (it) 2023-09-06
JP2022536287A (ja) 2022-08-15
MA56187A (fr) 2022-04-20
ZA202110685B (en) 2024-06-26
MA56187B1 (fr) 2023-09-27
IL288615A (en) 2022-02-01
TW202112370A (zh) 2021-04-01
FI3982960T3 (fi) 2023-08-29
JP2025124716A (ja) 2025-08-26
MY205687A (en) 2024-11-06
GB201910116D0 (en) 2019-08-28
AR119158A1 (es) 2021-12-01
UA129869C2 (uk) 2025-08-27
MX2021014557A (es) 2022-01-11
PH12021552966A1 (en) 2022-07-25
KR20220024220A (ko) 2022-03-03
EA202193019A1 (ru) 2022-03-24
HUE063163T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7688078B2 (ja) 遺伝性血管性浮腫の治療
JP7640474B2 (ja) 血管性浮腫の治療
US20240122909A1 (en) Treatments of hereditary angioedema
US20230381162A1 (en) Treatments of angioedema
HK40101443A (en) Treatments of hereditary angioedema
HK40070596B (en) Treatments of hereditary angioedema
HK40070596A (en) Treatments of hereditary angioedema
EA048676B1 (ru) Лечение наследственного ангионевротического отека
EP4673437A1 (en) New solid form of a plasma kallikrein inhibitor
JP2022069377A (ja) 血管性浮腫の処置
WO2025172693A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination